PeptideStack
5.2kquestions
20kanswers
220users

Why does racemisation accelerate at 40 °C rather than proceeding linearly?

Asked 14 Nov 2024Modified 17 months agoViewed 26k times
12

Details up front: racemisation · 40 °C.

I suspect the usual explanation for this is wrong, or at least incomplete.

I am aware this may have a boring answer. I would still like the boring answer stated clearly.

Can someone derive this rather than assert it?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

503 questions
shareeditfollowflag
TM
askedthermal_mass13k1714 Nov 2024
8Do you know the residual moisture? It predicts this better than any date does. – g_paskevicius 7 months ago
add a comment

5 Answers

Accepted answer first, then by votes
-3

Accepted answer

Because temperature enters the rate constant through an exponential, so equal steps in temperature multiply the rate instead of adding to it. Arrhenius puts the rate proportional to exp(−Ea/RT); the working approximation is a doubling per 10 K, which takes 5, 15, 25 and 35 °C to multipliers of 1, 2, 4 and 8. The steps in temperature are equal and the steps in rate are not, and that is the whole of the observation. At 40 °C the same rule gives about 11 times the refrigerated rate, and another 10 K would roughly double it again. A stereocentre inverts. Identical mass, identical formula; only a chiral method or a peptide map with a chiral digestion sees it at all. Ea differs by route, so the ranking of routes changes with temperature too — which is why accelerated data extrapolates badly and why nobody should read a 40 °C study as a fast version of a 5 °C one.

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

At dilute concentrations, suspect adsorption before you suspect chemistry.

shareimprove this answerflag
P9
answered · acceptedplate_count_9k78k24810 Feb 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
58

The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.

Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

Sequence decides which pathways are even available. Check the residues.

shareimprove this answerflag
MV
answeredmala_venkatesh22k3718 Jan 2025
40

Start with the sequence, because which pathways are available depends on which residues are present.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Stated carefully, light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.

Cold, dry, dark, still. Those four words cover most of the mitigation.

shareimprove this answerflag
HP
answeredh_pergande71k1587 Jan 2025
7Same experience here, different supplier. – Dr_Ingrid_Baumgartner 6 months ago
6Worth adding that residual moisture predicts this better than any printed date. – Dr_Rosalind_Achebe 5 months ago
add a comment
26

The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

Sequence determines which pathways apply, so general statements are general.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

edited 6 Feb 2025 by meniscus_film — added the method parameters

shareimprove this answerflag
MF
answeredmeniscus_film32k2730 Jan 2025
18

This is answerable from the chemistry rather than from anecdote, which is unusual and welcome.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

shareimprove this answerflag
PM
answeredpieter_maas14k174 Mar 2025
7I have kept vials both ways for a year and this matches what I saw. – gradient_slope 3 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.